G-Therapeutics, based in Switzerland, is the recipient of a 2014 sponsorship from Will2Walk Foundation in the amount of $5,000. G-Therapeutics is developing a therapeutic intervention for paraplegic individuals to restore voluntary motor control of the paralyzed limbs. The Will2Walk sponsorship was granted to partly cover expenses for the company’s attendance at Masschallenge in Boston.
G-Therapeutics aims to make available for human use a fundamentally new treatment paradigm that restored voluntary locomotion in fully paralyzed animals with a success rate of 100%. The company is developing an implantable stimulation system and a robot-assisted training program to rehabilitate individuals with spinal cord injury. A clinical proof in humans is planned.
The team used the trip to the world’s largest start-up accelerator to establish critical connections with key opinion leaders in the field of medical devices and rehabilitation centers in the United States and to better understand the regulatory processes required to get their therapy approved by the FDA.
The Will2Walk Scholarship & Sponsorship Program is designed to provide funding to individuals and qualified organizations that exemplify how those with spinal cord injuries can live a healthy, active and independent lifestyle. If you or someone you know could benefit from the Will2Walk Scholarship & Sponsorship Program, details can be found at Will2Walk.org.